+1 347 708 0418
The Novel Coronavirus (COVID-19) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Novel Coronavirus (COVID-19) Vaccine size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Novel Coronavirus (COVID-19) Vaccine market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Novel Coronavirus (COVID-19) Vaccine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
DNA
RNA
Others
Market segment by Application, can be divided into
Mild Symptom Patient
Critically Ill Patient
Market segment by players, this report covers
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Novel Coronavirus (COVID-19) Vaccine
1.2 Classification of Novel Coronavirus (COVID-19) Vaccine by Type
1.2.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2020
1.2.3 DNA
1.2.4 RNA
1.2.5 Others
1.3 Global Novel Coronavirus (COVID-19) Vaccine Market by Application
1.3.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Global Novel Coronavirus (COVID-19) Vaccine Market Size & Forecast
1.5 Global Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast by Region
1.5.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region, (2016-2021)
1.5.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2016-2026)
1.5.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2016-2026)
1.5.6 South America Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Novel Coronavirus (COVID-19) Vaccine Market Drivers
1.6.2 Novel Coronavirus (COVID-19) Vaccine Market Restraints
1.6.3 Novel Coronavirus (COVID-19) Vaccine Trends Analysis
2 Company Profiles
2.1 Inovio Pharmaceuticals
2.1.1 Inovio Pharmaceuticals Details
2.1.2 Inovio Pharmaceuticals Major Business
2.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Inovio Pharmaceuticals Recent Developments and Future Plans
2.2 Takis Biotech (Evvivax)
2.2.1 Takis Biotech (Evvivax) Details
2.2.2 Takis Biotech (Evvivax) Major Business
2.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Takis Biotech (Evvivax) Recent Developments and Future Plans
2.3 Zydus Cadila
2.3.1 Zydus Cadila Details
2.3.2 Zydus Cadila Major Business
2.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Zydus Cadila Recent Developments and Future Plans
2.4 Codagenix, Inc.
2.4.1 Codagenix, Inc. Details
2.4.2 Codagenix, Inc. Major Business
2.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Codagenix, Inc. Recent Developments and Future Plans
2.5 GeoVax, Inc.
2.5.1 GeoVax, Inc. Details
2.5.2 GeoVax, Inc. Major Business
2.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 GeoVax, Inc. Recent Developments and Future Plans
2.6 Bravovax
2.6.1 Bravovax Details
2.6.2 Bravovax Major Business
2.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Bravovax Recent Developments and Future Plans
2.7 Janssen Pharmaceutical Companies
2.7.1 Janssen Pharmaceutical Companies Details
2.7.2 Janssen Pharmaceutical Companies Major Business
2.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Janssen Pharmaceutical Companies Recent Developments and Future Plans
2.8 Altimmune
2.8.1 Altimmune Details
2.8.2 Altimmune Major Business
2.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Altimmune Recent Developments and Future Plans
2.9 Vaxart
2.9.1 Vaxart Details
2.9.2 Vaxart Major Business
2.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Vaxart Recent Developments and Future Plans
2.10 CanSino Biologics
2.10.1 CanSino Biologics Details
2.10.2 CanSino Biologics Major Business
2.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 CanSino Biologics Recent Developments and Future Plans
2.11 ExpreS2ion Biotechnologies ApS
2.11.1 ExpreS2ion Biotechnologies ApS Details
2.11.2 ExpreS2ion Biotechnologies ApS Major Business
2.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
2.12 Clover Biopharmaceuticals
2.12.1 Clover Biopharmaceuticals Details
2.12.2 Clover Biopharmaceuticals Major Business
2.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Clover Biopharmaceuticals Recent Developments and Future Plans
2.13 GSK
2.13.1 GSK Details
2.13.2 GSK Major Business
2.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.13.4 GSK Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 GSK Recent Developments and Future Plans
2.14 Vaxil Bio Ltd.
2.14.1 Vaxil Bio Ltd. Details
2.14.2 Vaxil Bio Ltd. Major Business
2.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Vaxil Bio Ltd. Recent Developments and Future Plans
2.15 Generex
2.15.1 Generex Details
2.15.2 Generex Major Business
2.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.15.4 Generex Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Generex Recent Developments and Future Plans
2.16 Novavax, Inc.
2.16.1 Novavax, Inc. Details
2.16.2 Novavax, Inc. Major Business
2.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Novavax, Inc. Recent Developments and Future Plans
2.17 Sanofi Pasteur
2.17.1 Sanofi Pasteur Details
2.17.2 Sanofi Pasteur Major Business
2.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Sanofi Pasteur Recent Developments and Future Plans
2.18 Baylor
2.18.1 Baylor Details
2.18.2 Baylor Major Business
2.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Baylor Recent Developments and Future Plans
2.19 iBio, Inc.
2.19.1 iBio, Inc. Details
2.19.2 iBio, Inc. Major Business
2.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 iBio, Inc. Recent Developments and Future Plans
2.20 Moderna, Inc.
2.20.1 Moderna, Inc. Details
2.20.2 Moderna, Inc. Major Business
2.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 Moderna, Inc. Recent Developments and Future Plans
2.21 Curevac
2.21.1 Curevac Details
2.21.2 Curevac Major Business
2.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Curevac Recent Developments and Future Plans
2.22 ImmunoPrecise
2.22.1 ImmunoPrecise Details
2.22.2 ImmunoPrecise Major Business
2.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions
2.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 ImmunoPrecise Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Novel Coronavirus (COVID-19) Vaccine Players Market Share
3.2.2 Top 10 Novel Coronavirus (COVID-19) Vaccine Players Market Share
3.2.3 Market Competition Trend
3.3 Novel Coronavirus (COVID-19) Vaccine Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Market Share by Type (2016-2021)
4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2016-2021)
5.2 Novel Coronavirus (COVID-19) Vaccine Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2026)
6.2 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2026)
6.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country
6.3.1 North America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2026)
6.3.2 United States Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
6.3.3 Canada Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
6.3.4 Mexico Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2026)
7.2 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2026)
7.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country
7.3.1 Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2026)
7.3.2 Germany Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
7.3.3 France Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
7.3.5 Russia Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
7.3.6 Italy Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2026)
8.2 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2026)
8.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region
8.3.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2016-2026)
8.3.2 China Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
8.3.3 Japan Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
8.3.4 South Korea Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
8.3.5 India Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
8.3.7 Australia Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2026)
9.2 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2026)
9.3 South America Novel Coronavirus (COVID-19) Vaccine Market Size by Country
9.3.1 South America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2026)
9.3.2 Brazil Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
9.3.3 Argentina Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2026)
10.2 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2026)
10.3 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country
10.3.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2026)
10.3.2 Turkey Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
10.3.4 UAE Novel Coronavirus (COVID-19) Vaccine Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Novel Coronavirus (COVID-19) Vaccine Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Region (2016-2021)
Table 5. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2021-2026)
Table 6. Inovio Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Inovio Pharmaceuticals Major Business
Table 8. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 9. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Takis Biotech (Evvivax) Corporate Information, Head Office, and Major Competitors
Table 11. Takis Biotech (Evvivax) Major Business
Table 12. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 13. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Zydus Cadila Corporate Information, Head Office, and Major Competitors
Table 15. Zydus Cadila Major Business
Table 16. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 17. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Codagenix, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Codagenix, Inc. Major Business
Table 20. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 21. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. GeoVax, Inc. Corporate Information, Head Office, and Major Competitors
Table 23. GeoVax, Inc. Major Business
Table 24. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 25. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Bravovax Corporate Information, Head Office, and Major Competitors
Table 27. Bravovax Major Business
Table 28. Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 29. Bravovax Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Janssen Pharmaceutical Companies Corporate Information, Head Office, and Major Competitors
Table 31. Janssen Pharmaceutical Companies Major Business
Table 32. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 33. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Altimmune Corporate Information, Head Office, and Major Competitors
Table 35. Altimmune Major Business
Table 36. Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 37. Altimmune Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Vaxart Corporate Information, Head Office, and Major Competitors
Table 39. Vaxart Major Business
Table 40. Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 41. Vaxart Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. CanSino Biologics Corporate Information, Head Office, and Major Competitors
Table 43. CanSino Biologics Major Business
Table 44. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 45. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. ExpreS2ion Biotechnologies ApS Corporate Information, Head Office, and Major Competitors
Table 47. ExpreS2ion Biotechnologies ApS Major Business
Table 48. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 49. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Clover Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Clover Biopharmaceuticals Major Business
Table 52. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 53. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. GSK Corporate Information, Head Office, and Major Competitors
Table 55. GSK Major Business
Table 56. GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 57. GSK Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Vaxil Bio Ltd. Corporate Information, Head Office, and Major Competitors
Table 59. Vaxil Bio Ltd. Major Business
Table 60. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 61. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Generex Corporate Information, Head Office, and Major Competitors
Table 63. Generex Major Business
Table 64. Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 65. Generex Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Novavax, Inc. Corporate Information, Head Office, and Major Competitors
Table 67. Novavax, Inc. Major Business
Table 68. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 69. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Sanofi Pasteur Corporate Information, Head Office, and Major Competitors
Table 71. Sanofi Pasteur Major Business
Table 72. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 73. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Baylor Corporate Information, Head Office, and Major Competitors
Table 75. Baylor Major Business
Table 76. Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 77. Baylor Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. iBio, Inc. Corporate Information, Head Office, and Major Competitors
Table 79. iBio, Inc. Major Business
Table 80. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 81. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Moderna, Inc. Corporate Information, Head Office, and Major Competitors
Table 83. Moderna, Inc. Major Business
Table 84. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 85. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Curevac Corporate Information, Head Office, and Major Competitors
Table 87. Curevac Major Business
Table 88. Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 89. Curevac Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. ImmunoPrecise Corporate Information, Head Office, and Major Competitors
Table 91. ImmunoPrecise Major Business
Table 92. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions
Table 93. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Players (2019-2021)
Table 95. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players (2019-2021)
Table 96. Breakdown of Novel Coronavirus (COVID-19) Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 97. Novel Coronavirus (COVID-19) Vaccine Players Head Office, Products and Services Provided
Table 98. Novel Coronavirus (COVID-19) Vaccine Mergers & Acquisitions in the Past Five Years
Table 99. Novel Coronavirus (COVID-19) Vaccine New Entrants and Expansion Plans
Table 100. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Type (2016-2021)
Table 101. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Type (2016-2021)
Table 102. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Type (2021-2026)
Table 103. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2021)
Table 104. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Application (2021-2026)
Table 105. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2021) & (USD Million)
Table 106. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 107. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2021) & (USD Million)
Table 108. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 109. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2021) & (USD Million)
Table 110. North America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 111. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2021) & (USD Million)
Table 112. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 113. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2021) & (USD Million)
Table 114. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 115. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2021) & (USD Million)
Table 116. Europe Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 117. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2021) & (USD Million)
Table 118. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 119. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2021) & (USD Million)
Table 120. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 121. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2016-2021) & (USD Million)
Table 122. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue by Region (2021-2026) & (USD Million)
Table 123. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2021) & (USD Million)
Table 124. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 125. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2021) & (USD Million)
Table 126. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 127. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2021) & (USD Million)
Table 128. South America Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 129. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2016-2021) & (USD Million)
Table 130. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 131. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2016-2021) & (USD Million)
Table 132. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 133. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2016-2021) & (USD Million)
Table 134. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Novel Coronavirus (COVID-19) Vaccine Picture
Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2020
Figure 3. DNA
Figure 4. RNA
Figure 5. Others
Figure 6. Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2020
Figure 7. Mild Symptom Patient Picture
Figure 8. Critically Ill Patient Picture
Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2016-2026)
Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region in 2020
Figure 13. North America Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Novel Coronavirus (COVID-19) Vaccine Market Drivers
Figure 19. Novel Coronavirus (COVID-19) Vaccine Market Restraints
Figure 20. Novel Coronavirus (COVID-19) Vaccine Market Trends
Figure 21. Inovio Pharmaceuticals Recent Developments and Future Plans
Figure 22. Takis Biotech (Evvivax) Recent Developments and Future Plans
Figure 23. Zydus Cadila Recent Developments and Future Plans
Figure 24. Codagenix, Inc. Recent Developments and Future Plans
Figure 25. GeoVax, Inc. Recent Developments and Future Plans
Figure 26. Bravovax Recent Developments and Future Plans
Figure 27. Janssen Pharmaceutical Companies Recent Developments and Future Plans
Figure 28. Altimmune Recent Developments and Future Plans
Figure 29. Vaxart Recent Developments and Future Plans
Figure 30. CanSino Biologics Recent Developments and Future Plans
Figure 31. ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
Figure 32. Clover Biopharmaceuticals Recent Developments and Future Plans
Figure 33. GSK Recent Developments and Future Plans
Figure 34. Vaxil Bio Ltd. Recent Developments and Future Plans
Figure 35. Generex Recent Developments and Future Plans
Figure 36. Novavax, Inc. Recent Developments and Future Plans
Figure 37. Sanofi Pasteur Recent Developments and Future Plans
Figure 38. Baylor Recent Developments and Future Plans
Figure 39. iBio, Inc. Recent Developments and Future Plans
Figure 40. Moderna, Inc. Recent Developments and Future Plans
Figure 41. Curevac Recent Developments and Future Plans
Figure 42. ImmunoPrecise Recent Developments and Future Plans
Figure 43. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players in 2020
Figure 44. Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 45. Global Top 3 Players Novel Coronavirus (COVID-19) Vaccine Revenue Market Share in 2020
Figure 46. Global Top 10 Players Novel Coronavirus (COVID-19) Vaccine Revenue Market Share in 2020
Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 48. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Type in 2020
Figure 49. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Type (2021-2026)
Figure 50. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Application in 2020
Figure 51. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Application (2021-2026)
Figure 52. North America Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Type (2016-2026)
Figure 53. North America Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Application (2016-2026)
Figure 54. North America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Country (2016-2026)
Figure 55. United States Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Canada Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Mexico Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Europe Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Type (2016-2026)
Figure 59. Europe Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Application (2016-2026)
Figure 60. Europe Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Country (2016-2026)
Figure 61. Germany Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. France Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. United Kingdom Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Russia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Italy Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Type (2016-2026)
Figure 67. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Application (2016-2026)
Figure 68. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2016-2026)
Figure 69. China Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Japan Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. South Korea Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. India Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Australia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South America Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Type (2016-2026)
Figure 76. South America Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Application (2016-2026)
Figure 77. South America Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Country (2016-2026)
Figure 78. Brazil Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Argentina Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Type (2016-2026)
Figure 81. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Sales Market Share by Application (2016-2026)
Figure 82. Middle East and Africa Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Country (2016-2026)
Figure 83. Turkey Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. UAE Novel Coronavirus (COVID-19) Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Methodology
Figure 87. Research Process and Data Source
Buy
